Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.

Next Previous
Trial Profile

An observational, multicentre, open label non interventional programme to assess the long-term safety and efficacy of Somatuline (registered trade mark) Autogel (registered trade mark) in the treatment of neuroendocrine tumours when administered by patients or their partners ("Home Injection Group") or administered by healthcare professionals.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Neuroendocrine tumours
  • Focus Adverse reactions
  • Sponsors Ipsen

Most Recent Events

  • 06 Dec 2013 Planned number of patients changed from 30 to 25 as reported by Australian New Zealand Clinical Trials Registry record.
  • 06 Dec 2013 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry record.
  • 06 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top